Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.
Safety and Tolerability of Glatiramer Acetate (GLACIER)
Physiotherapy as an immunoactive therapy? A pilot study.
AMP-Activated Protein Kinase Restricts IFN-γ Signaling.
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.
A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Distinct profiles of myelin distribution along single axons of pyramidal neurons in the neocortex.
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.
Transcriptional enhancers: from properties to genome-wide predictions.
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis-Report of Two Cases.
Genome-wide pathway analysis of a genome-wide association study on multiple sclerosis.
Subclinical CNS Inflammation as Response to a Myelin Antigen in Humanized Mice.
From injection therapies to natalizumab: views on the treatment of multiple sclerosis.
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Tractography Analysis of 5 White Matter Bundles and Their Clinical and Cognitive Correlates in Early-Course Schizophrenia.
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.
Drug record: Amiloride
miR-15a and 16-1 are downregulated in CD4(+) T cells of multiple sclerosis relapsing patients.
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide.
Genetic burden of common variants in progressive and bout-onset multiple sclerosis.
Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis.
Pages
« first
‹ previous
…
126
127
128
129
130
131
132
133
134
…
next ›
last »